(Q38177186)

30 August 2017

title

Anti-interleukin-1 therapy in the management of gout (English)

1 reference

30 August 2017

Naomi Schlesinger

1

1 reference

30 August 2017

publication date

1 February 2014

1 reference

Current Rheumatology Reports

30 August 2017

published in

1 reference

30 August 2017

volume

16

1 reference

30 August 2017

issue

2

1 reference

30 August 2017

page(s)

398

1 reference

Prevalence of contraindications and prescription of pharmacologic therapies for gout.

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0398-Z

MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0398-Z

Gout-associated uric acid crystals activate the NALP3 inflammasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0398-Z

The inflammatory process of gout and its treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0398-Z

A pilot study of IL-1 inhibition by anakinra in acute gout

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0398-Z

Anakinra's efficacy is variable in refractory gout: report of ten cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0398-Z

Efficacy of anakinra in gouty arthritis: a retrospective study of 40 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0398-Z

Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0398-Z

The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0398-Z

Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0398-Z

Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0398-Z

Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0398-Z

Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0398-Z

Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0398-Z

Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study

21 January 2018

1 reference

12 December 2020

Interleukin 1 (IL 1) as a mediator of crystal arthritis. Stimulation of T cell and synovial fibroblast mitogenesis by urate crystal-induced IL 1.

1 reference

12 December 2020

[Treatment of rheumatoid arthritis with anakinra: a systematic review]

1 reference

12 December 2020

Rilonacept (arcalyst), an interleukin-1 trap for the treatment of cryopyrin-associated periodic syndromes.

1 reference

12 December 2020

Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a phase II randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008

1 reference

12 December 2020

10.1007/S11926-013-0398-Z

Identifiers

DOI

1 reference

Dimensions Publication ID

30 August 2017

1015608796

0 references

1 reference